ARVO 2020: Two-year anatomical outcomes of FAc in DME patients


Victor Gonzalez, MD, speaks with Ophthalmology Times® David Hutton on the highlights of his presentation regarding "Two-year outcomes from the PALADIN Phase 4 study: Anatomic/functional changes and reduced treatment frequency associated with 0.19 mg of fluocinolone acetonide implant (FAc) with persistent or recurrent diabetic macular edema," during the 2020 Association for Research in Vision and Ophthalmology (ARVO) virtual meeting.

See more ARVO coverage here

Related Videos
This series features 1 KOL.
This series features 1 KOL.
This series features 1 KOL.
Video 2 - 1 KOL is featured in, "Advances in Technology for SMILE procedure"
Video 1 - 1 KOL is featured in, "Overview of Small Incision Lenticule Extraction (SMILE)"
Vicki Chan, MD, shares pearls for leveraging the power of social media in health care
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
© 2024 MJH Life Sciences

All rights reserved.